乳腺癌患者的连续中度低分化增长:对晚期副作用的单一机构分析
Isabella Palumbo1, Anna Giulia Becchetti2, Elisabetta Perrucci3
1Radiation Oncology Section, University of Perugia and Perugia General Hospital, Perugia, Italy; isabella.palumbo@unipg.it.
Anticancer research
|August 28, 2024
概括
在全乳房照射 (HF-WBI) 后的低分量增强 (HB) 对乳腺癌患者是安全的. 长期随访显示副作用最小,支持其在常规实践中的使用.
科学领域:
- 在瘤学瘤学.
- 辐射疗法 辐射疗法
- 乳腺癌治疗方法 乳腺癌治疗方法
背景情况:
- 中度低分化 (HF-WBI) 是乳房保护手术的标准.
- 提升分成方案需要进一步定义.
- 之前的研究评估了顺序性低分离增强 (HB) 的急性/晚期副作用.
研究的目的:
- 在更长的随访中评估HF-WBI后HB的晚期副作用.
- 在乳腺癌患者中评估HB的安全性和耐受性.
- 确定晚期毒性的预测因素.
主要方法:
- 219名乳腺癌患者接受了HF-WBI (42.4 Gy/16分).
- 具有负预后因素的患者接受HB (2.65 Gy/4-5分数).
- 使用CTCAE v5.0评估的晚期副作用;进行了单变量/多变量分析.
主要成果:
- 随访时间中位数:8.6年;评估了165名患者.
- 15.8%的人经历了1级晚期皮肤/皮下副作用.
- 切除的淋巴结 (≥10) 是晚期毒性的重要危险因素 (多变量分析).
结论:
- 在HF-WBI之后的低分量增量 (HB) 是安全的,并且耐受良好.
- 长期跟踪证实了最小的晚期毒性.
- 可以将HB整合到常规乳腺癌治疗方案中.
更多相关视频
相关概念视频
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Cancer Survival Analysis
334
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
334


